bioAffinity Technologies, Inc. (BIAFW) stock
BIAFWNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31Also trades as BIAF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 4/3056% below fair value
$0.24+0.00 (0.00%)
Close on Oct 30, 2026Market cap $23.58MP/E –Yield –
bioAffinity Technologies ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
bioAffinity Technologies's ebitda for the twelve months ending Jun 30, 2026 was -$11.97M. For fiscal 2025 it was -$10.07M. The highest annual figure on record is -$2.20M in fiscal 2021.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$10.07M | – |
| FY2024 | Dec 31, 2024 | -$8.35M | – |
| FY2023 | Dec 31, 2023 | -$7.72M | – |
| FY2022 | Dec 31, 2022 | -$4.00M | – |
| FY2021 | Dec 31, 2021 | -$2.20M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$3.27M | – |
| Q1 FY2026 | Mar 31, 2026 | -$3.50M | – |
| Q4 FY2025 | Dec 31, 2025 | -$3.01M | – |
| Q3 FY2025 | Sep 30, 2025 | -$2.18M | – |
| Q2 FY2025 | Jun 30, 2025 | -$2.40M | – |
| Q1 FY2025 | Mar 31, 2025 | -$2.47M | – |
| Q4 FY2024 | Dec 31, 2024 | -$2.79M | – |
| Q3 FY2024 | Sep 30, 2024 | -$1.82M | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.94M | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.80M | – |
| Q4 FY2023 | Dec 31, 2023 | -$2.19M | – |
| Q3 FY2023 | Sep 30, 2023 | -$2.24M | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.76M | – |
| Q1 FY2023 | Mar 31, 2023 | -$1.54M | – |
| Q4 FY2022 | Dec 31, 2022 | -$1.62M | – |
| Q3 FY2022 | Sep 30, 2022 | -$975.38K | – |
| Q2 FY2022 | Jun 30, 2022 | -$683.08K | – |
| Q1 FY2022 | Mar 31, 2022 | -$726.00K | – |
| Q4 FY2021 | Dec 31, 2021 | -$658.96K | – |
| Q3 FY2021 | Sep 30, 2021 | -$525.09K | – |